The Home of Adult Stem Cell News and Information
For the first time in Singapore, stem cells from the umbilical cord have been used to treat cerebral palsy – and with positive results.
For the last month, we’ve introduced you to several local families who bear the burden of Autism on a daily basis. They make the most of their situation knowing there’s no known cure for Autism and the cause is still very much a mystery. Here’s the statistic. 1 child in every 110 will be born with Autism. That means roughly 97 children born today will be diagnosed with Autism and it doesn’t stop there either. More than 1.5 million Americans live with the disorder which is the fastest growing brain disability in the country with an annual growth rate around 17%. Currently there is no cure, but that could be changing in part to what could be one of the biggest medical breakthroughs in history. And it’s being done with what doctors once deemed medical waste. The phenomenon is called cord blood banking and this week I had the chance to see the process first hand at the Cord Blood Registry, CBR, in Tucson, Arizona. It’s the world’s largest cord blood bank with more than 300000 stored and it has the chance to change the face of medicine forever. “It’s almost as if a light bulb went off in their child’s brain. Their vocabulary starts to increase. They just seem more with it, more alert,” said Christine McMurry, communications director with CBR out of Tucson. Cord blood banking is a process in which parents choose to have the blood from their child’s umbilical cord stored at birth where it will stay until it’s needed again for an infusion or transplant. “In cord blood, it’s new …
Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.
“We are asked with some frequency why store these stem cells available only at birth. On our web site at www.corcell.com is a list of more than 70 diseases that are already treated by these stem cells, including acute and chronic leukemia’s, severe aplastic anemia, Hodgkin’s Disease, a number of inherited metabolic diseases and immune system disorders and malignancies including Ewing Sarcoma and Sickle Cell Disease,” said Matthew Schissler, co-founder and CEO. ”Once in a while, it is my duty and obligation to step away from the day-to-day and reflect on the larger scope of work in the umbilical cord blood stem cell arena. In doing so, I recognize that our loyal shareholders may not be privy to all of the data we receive, involving the outstanding studies with these cells. It is my hope that a simple statement such as this, can direct our shareholders to the resources publicly available.”
“What is truly exciting is that the National Institutes of Health at www.clinicaltrials.gov now lists clinical trials ongoing at such prestigious research institutions as Duke University and Memorial Sloan-Kettering Cancer Center to understand the possible usage of stem cell infusions for the treatment of intractable diseases, including Type I diabetes in children, cerebral palsy in children, chronic spinal cord injuries, lymphoma and other blood borne cancers,” Mr. Schissler said.
“Also, there is research ongoing elsewhere in the world to use umbilical cord blood stem cells to combat Alzheimer’s, cardiac disease, lupus, multiple sclerosis, muscular dystrophy, Parkinson’s Disease, rheumatoid arthritis and stroke. This truly is an excellent time to be involved in this sector as we work toward our goal of becoming the most significant stem cell company in the world,” said Mr. Schissler.
Cleveland, Ohio leveraged buyout firm Riverside Co. has acquired private cord blood bank Celvitae Biomedica S.A. in Madrid, Spain for undisclosed terms.
Celvitae is one of two cord blood banks licensed in Spain and authorized to work in the public health system, Riverside said in a release. It also has major commercial agreements with some of the leading insurance companies in the Spanish market.
Last year, Celvitae struck a strategic agreement with MD Anderson Internacional Espana, a cancer treatment center in Europe that ensures all cord blood stem cell samples collected in Spain are processed within 24 hours at its Madrid facilities.
). On * average, the noscript tag is called from less than 1% of internet * users. */–>
Riverside will add Celvitae to its Crioestaminal platform, the Cantanhede, Portugal company that is a pioneer and market leader in the isolation and storage of cord blood stem cells. More than 40,000 parents have trusted the company to store their children’s stem cells.
Riverside acquired Crioestaminal last year. The Celvitae acquisition was made from Riverside Europe Fund IV. Riverside is co-headquartered in New York City.
This is me explaining how to care for your babies umbilical cord care and a bit of advice on cord blood banking. www.babycenter.com www.cordblood.com www.mayoclinic.com
www.hotstocked.com Everything looks great in Cordblood America, Inc (OTC:CBAI), especially their brand new headquarters. The only problem is that after they bragged of getting rid of the debt, they started borrowing again. This and stock sales is how they keep surviving.
DISCLAIMER: Please consult with your primary care physician before starting this or any other natural supplement. To learn more about cord blood banking see: www.cordblood.com To register, ask for Erin and tell her that Dr. Ahuva Gamliel referred you! Use the mom code: M1975 to save $250 when you enroll on-line or save $150 when you enroll by phone! To learn more about enhancing your health & wellbeing by boosting your own stem cells watch the 9 minute video on optimalhealth613.stemtechbiz.com For more information see: www.DrGamliel.com Please share this potentially life-saving information with a friend!
This video reviews the benefits of cord blood stem cells and the differences between cord blood stem cells and embryonic or adult stem cells. Cord blood stem cells have been used as a treatment for thousands of patients, while embryonic stem cells have never been used as a treatment in humans. For a free information kit, click here www.cordblood.com … Cord blood Stem Cells Pregnancy Baby Diabetes Leukemia Cancer Sickle Cell Anemia Heart Disease Health Medicine …
LifeCell International India’s first & the largest stem cell banking service provider, which has also pioneered in stem cell research and technology, today announced its association with Harvest Technologies, a world leader in developing technologies that accelerate natural healing, to bring-in a next generation technology Bone Marrow Aspirate Concentrate (BMAC) system in India. BMAC is a USFDA and CE approved biological technology that accelerates the body’s natural healing capacity, thereby improving surgical outcomes.
Existing methods to produce a stem cell concentrate therapy are time consuming, labour intensive, and require complex logistical considerations. The BMAC System helps in safe and rapid preparation of cell concentrate from bone marrow. The process takes only about 15 minutes and can be conducted in the point of care setting.
The system is currently being used clinically in many developed countries like US and Europe for various medical disciplines. These applications range from fractures, non-unions, osteonecrosis, cartilage repair applications and critical limb ischemia (CLI). The system will soon be applied for cardio vascular regeneration.
LifeCell has implemented this technology for an ongoing Indian CLI study which is being led by Dr. K. S. Vijayragavan at Department of Vascular Surgery, SRMC. As per the data available on the interim study conduted on 30 patients after a 12 week followup major amputations were seen only in 4 patients and 6 of them went for minor amputation. The patients’s also reported significant reduction in their pain perception and considerable improvement in quality of life. The study also emphasised the fact that the BMAC process is safe and the Intra-arterial infusion does not cause any adverse reaction.
Talking on the association with Harvest Technologies, Mr. Mayur Abhaya, Executive Director, LifeCell International says, “We are excited to partner with Harvest Technologies to bring-in international standards to India. LifeCell International is today India’s only comprehensive stem cells solutions provider as we offer a complete spectrum of services and with this association we intend to accelerate the availability of advanced stem cell therapy in India.
According to Scott Shea, Managing Director, Harvests Technologies GmbH, “The Autologous regenerative cells from bone marrow offer profound potential for therapies. Harvest has conducted about 30,000 clinical procedures for various applications, the highest number of procedures in the world, using the BMAC System. Our novel technology now makes it possible to harvest the regenerative cells safely and rapidly in order to develop new therapies for heretofore incurable diseases.”
“We are delighted to be associated with LifeCell, an undisputed market leader in stem cell technology space and extend our services in India. LifeCell has a well established network with hospitals and clinical institutions across India and we would leverage their strength to rapidly deploy our service across the country and provide HOPE in addressing unmet medical challenges by offering cellular therapeutic options.”
Commenting on the interim report presented on the studies conducted for CLI in India using the BMAC technology, Mr. Mayur added, “Through our clinical research, we have identified that the transplantation of autologous Bone Marrow Aspirate Concentrate (BMAC) into critically ischemic leg can increase blood flow and support in healing the wounds quickly. It also helps in reducing pain and avoiding leg amputation of otherwise incurable patients. This is also validated by the outcome of the CLI study which showed that 86.6% of patients could avoid amputation.”
About LifeCell International Pvt. Ltd: LifeCell is India’s first & largest umbilical cord blood stem cell bank to bring the revolutionary concept of banking a baby’s umbilical cord blood stem to the country. LifeCell facilitates the cryogenic preservation of stem cells in technological collaboration with Cryo-Cell International Inc, USA – the world’s largest and oldest stem cell bank with more than 16 years of expertise in stem cell banking.
LifeCell in the past 4 years has positioned itself as leaders in the Industry and was recently accredited by AABB (American Association of Blood Banks) for adopting their international standards and today LifeCell is the “First & only AABB Accredited Stem Cell Bank in India” and recognized by DSIR, Govt. of India for R&D. Today LifeCell has over 20,000 members who have preserved their baby’s cord blood stem cells and has over 40 centers across India and abroad. The company will soon be launching another revolutionary service of Menstrual Blood Stem Cell Banking for every woman to preserve her stem cells and potentially secure her future from life-threatening diseases. With addition of this service LifeCell will become the first & only comprehensive stem cells solutions provider in the world to offer a complete spectrum of services in stem cells through multi-service banking, R&D, Clinical Trials and Stem Cell Therapy.
Blood can be collected from the umbilical cord of a newborn baby shortly after birth. This blood is rich in blood stem cells that can be used to generate red blood cells and cells of the immune system. Cord Blood stem cells can be used to treat a range of blood disorders and immune system conditions such as leukaemia, anaemia and autoimmune diseases. Once collected, cord blood can be stored in a cord blood bank and would be available for use by the donor and compatible siblings.
Alternatively, the cord blood may be donated to a general cord blood bank for use by other tissue matched individuals in need of a transplant. It is hoped that over time a store of cord blood stem cells from people of different tissue types may be established. Someone requiring a transplant would be treated with stem cells from the sample most closely matching their own tissue type, thus minimising complications associated with immune rejection.
Cord blood stem cells may also be useful for treatment of diseases other than blood disorders. Preliminary research reports suggest that cord blood stem cells may have a greater ability to differentiate into different cell types than was previously thought possible. Using animal model, several research groups have used human cord blood stem cells to treat heart attacks and repair injured blood vessels. However, this research is at a very early stage. Scientists are presently unsure whether the cord blood stem cells are transformed into heart muscle or blood vessels, or if they secrete growth factors, that trigger repair. If further studies and clinical trials prove successful, cord blood stem cells may provide a new treatment for cardiovascular disease with fewer side effects than current drug based and surgical treatments.
The use of cord blood stem cells in cell-based therapies for blood and immune diseases, and for other potential applications, would be welcomed by the majority of the community. Although cord blood stem cells are less versatile than Embryonic Stem cells, their use in research is less controversial as it does not involve the destruction of embryos. Their potential use for cell-based therapies is also attractive as it would be possible to use a patient’s own cord blood stem cells to generate tissue for transplantation, thus avoiding problems with immune rejection.
Controversy has arisen over the practice of genetically selecting embryos created during infertility treatment, for the purpose of using the donor baby’s cord blood to treat an ill sibling. In this procedure, genetic testing is performed to ensure that the embryo will provide cord blood devoid of the genetic defect afflicting the sibling, but which matches the sibling’s genetic make up. The donor baby in this case is sometimes referred to as a ‘savior sibling’.
The first ‘saviour sibling’ to be born in Australia was reported in March 2004. A Tasmanian couple used this technology to have a second child who was free of a genetic condition, Hyper IgM Syndrome. Cord blood from this child could be used to treat the affected sibling. As a result of this selection process carried out Sydney IVF Clinic, the woman started her pregnancy knowing that her baby was free of Hyper IgM Syndrome and would be a potential tissue donor for her existing son.
The creation of ‘saviour siblings’ has evoked a quite heated debate in both the medical and general community. Some are vehemently opposed to this application, considering this the first step in ‘designer babies’. Others consider it highly unethical not to use this technology to help the sick sibling. The overarching issue to be considered is the well being of the ‘savior sibling’, and to ask the question whether they will be disadvantaged by the procedure. These are questions to be considered by both the biomedical and general community when considering applications of any new technology.
using her brother’s cord blood stem cells is now living happily and actively. Angel’s family had no history of cancer in the family and they had no reason to store her cord blood stem cells when she was born but her brother’s matching stem cells were used to save her life. Her stem cell transplant was performed in 2004 in a Malaysian Public Hospital. … cordblood “cord blood” “stem cell” “cord blood banking” “stem cell transplant” leukemia child remission malaysia “stem cell bank” stemlife …
